Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Immunotech Biopharm Ltd ( (HK:6978) ) has provided an announcement.
Immunotech Biopharm Ltd announced the successful completion of its rights issue, which was significantly oversubscribed. The company raised approximately HK$257.29 million in gross proceeds, with net proceeds estimated at HK$251.88 million, which will be used according to their planned allocation. The oversubscription indicates strong investor confidence and could enhance the company’s financial position and operational capabilities.
More about Immunotech Biopharm Ltd
Immunotech Biopharm Ltd is a company incorporated in the Cayman Islands, operating in the biopharmaceutical industry. It focuses on developing and manufacturing innovative biopharmaceutical products, with a market focus on advancing healthcare solutions.
Average Trading Volume: 1,550,617
Technical Sentiment Signal: Sell
Current Market Cap: HK$2.03B
See more insights into 6978 stock on TipRanks’ Stock Analysis page.